Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 296Cytarabine 261fludarabine phosphate 218Rituximab 195fludarabine 182Methotrexate 152Whole-Body Irradiation 140Mycophenolic Acid 124Azacitidine 122Tacrolimus 116Busulfan 110Filgrastim 104Granulocyte Colony-Stimulating Factor 98Etoposide 91Peripheral Blood Stem Cell Transplantation 90Dexamethasone 89Vincristine 88Melphalan 80Cyclosporine 74Lenalidomide 73Daunorubicin 70Decitabine 69Clofarabine 69Antilymphocyte Serum 67Calcium Dobesilate 61venetoclax 60Doxorubicin 58Imatinib Mesylate 57Alemtuzumab 56ibrutinib 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × sapacitabine × Other hematologic neoplasm × Clear all
NCT00590187 2024-06-04

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

Cyclacel Pharmaceuticals, Inc.

Phase 2 Completed
105 enrolled 11 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01303796 2022-06-22

SEAMLESS

Cyclacel Pharmaceuticals, Inc.

Phase 3 Completed
482 enrolled 24 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01253460 2019-09-06

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

M.D. Anderson Cancer Center

Phase 2 Terminated
18 enrolled 10 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡